|Home | About | Journals | Submit | Contact Us | Français|
Low-density lipoprotein receptor-related protein-1 (LRP1), a member of the LDL receptor family, has major roles in the cellular transport of cholesterol, endocytosis of forty structurally diverse ligands, transcytosis of ligands across the blood-brain barrier, and transmembrane and nuclear signaling. Recent evidence indicates that LRP1 regulates brain and systemic clearance of Alzheimer's disease (AD) amyloid β-peptide (Aβ). According to the two hit vascular hypothesis for AD, vascular damage precedes cerebrovascular and brain Aβ accumulation (hit 1) which then further amplifies neurovascular dysfunction (hit 2) preceding neurodegeneration. In this study, we discuss the roles of LRP1 during the hit 1 and hit 2 stage of AD pathogenesis and describe a three-level serial LRP1-dependent homeostatic control of Aβ clearance including (i) cell-surface LRP1 at the BBB and cerebrovascular cells mediating brain-to-blood Aβ clearance (ii) circulating LRP1 providing a key endogenous peripheral ‘sink’ activity for plasma Aβ which prevents free Aβ access to the brain, and (iii) LRP1 in the liver mediating systemic Aβ clearance. Pitfalls in experimental Aβ brain clearance measurements with the concurrent use of peptides/proteins such as receptor-associated protein and aprotinin are also discussed. We suggest that LRP1 has a critical role in AD pathogenesis and is an important therapeutic target in AD.
The low-density lipoprotein receptor-related protein-1 (LRP1) is a multifunctional scavenger and signaling receptor that belongs to the low-density lipoprotein receptor family (Herz 2001; Herz and Strickland 2001). LRP1 has a major role in the transport and metabolism of cholesterol associated with apolipoprotein E (apoE)-containing lipoproteins (Herz 2001; Herz and Strickland 2001; Herz et al. 2009). The extracellular heavy α-chain of LRP1 (515 kDa) is noncovalently coupled to the 85 kDa transmembrane and cytoplasmic light β-chain domain (Fig. 1a). The α-chain contains four ligand-binding domains (clusters I-IV), consisting of 2, 8, 10 and 11 cysteine-rich complement-type repeats, respectively (Obermoeller-McCormick et al. 2001; Meijer et al. 2007). The LRP1 ligand-binding domains II and IV are the major LRP1 binding regions interacting with a diverse array of approximately forty structurally diverse ligands (Fig. 1b) including: apoE, α2-macroglobulin (α2M), tissue plasminogen activator (tPA), proteinase-inhibitors, blood coagulation factors (e.g., factor VIII), receptor-associated protein (RAP), Alzheimer's disease (AD) amyloid β-peptide (Aβ), prion protein and aprotinin (Hussain et al. 1999; Neels et al. 1999; Herz 2001; Herz and Strickland 2001; Croy et al. 2003; Deane et al. 2004a; Meijer et al. 2007; Demeule et al. 2008; Lillis et al. 2008; Parkyn et al. 2008; Herz et al. 2009).
The cytoplasmic tail of LRP1 contains two NPXY motifs, one YXXL motif and two di-leucine motifs (Li et al. 2001) (Fig. 1a). It has been suggested that the YXXL motif and distal di-leucine repeats may be associated with the rapid endocytotic rate of LRP1 (i.e., < 0.5 s) (Li et al. 2001; Deane et al. 2004a, 2008). The cytoplasmic tail is phosphorylated on serine and/or tyrosine residues (Bu et al. 1998; van der Geer 2002) and can interact with different adaptor proteins associated with cell signaling, such as disabled-1, FE65 and postsynaptic density protein 95 (Trommsdorff et al. 1998; Gotthardt et al. 2000; Herz et al. 2009). Thus, LRP1 has a dual role as a rapid cargo endocytotic cellular transporter and a transmembrane cell signaling receptor.
LRP1 is expressed in the CNS in different cell types within the neurovascular unit including vascular cells such as brain endothelial cells, vascular smooth muscle cells and pericytes, and is also expressed in neurons and astrocytes (Herz and Bock 2002; Polavarapu et al. 2007). Although LRP1 has been regarded mainly as a receptor which internalizes its ligands and directs them to the lysosomes for proteolytic degradation, recent studies have demonstrated that LRP1 can also transport several ligands transcellularly across the blood-brain barrier (BBB) including Aβ (Shibata et al. 2000; Deane et al. 2004a), RAP (Pan et al. 2004), tissue plasminogen activator (Benchenane et al. 2005), lipid free and lipidated apoE2 and apoE3, and apoE2 and apoE3 complexes with Aβ (Deane et al. 2008) and a family of Kunitz domain-derived peptides (Demeule et al. 2008). These findings suggest that LRP1 can control transport exchanges of several ligands between the brain and the blood.
Some genetic studies have suggested that LRP1 is linked to AD and cerebral amyloid angiopathy (CAA) (Kang et al. 1997; Lambert et al. 1998; Wavrant-DeVrieze et al. 1999; Christoforidis et al. 2005; Ballatore et al. 2007). This, however, has not been confirmed by others (Bertram et al. 2000; Chalmers et al. 2010). Moreover, two recent genome-wide association studies have reported that phosphatidylinositol binding clathrin assembly protein (PICALM, also known as CALM, clathrin assembly lymphoid-myeloid leukemia gene) and apoJ (also known as clusterin) are the only two AD susceptibility genes (Harold et al. 2009; Lambert et al. 2009) in addition to the apoE4 gene. The exact roles of PICALM and apoJ in AD pathogenesis are unclear at present (Bertram and Tanzi 2010). It has been shown that apoJ, a ligand for the lipoprotein receptor related protein-2 (LRP2; also known as megalin) controls Aβ transcytosis across the BBB through megalin-dependent rapid Aβ42 efflux from brain to blood (Bell et al. 2007). However, apoJ can also mediate re-entry of circulating Aβ into the brain (Zlokovic et al. 1996). On the other hand, PICALM regulates clathrin-dependent receptor-mediated endocytosis of several ligands (Tebar et al. 1999; Bushlin et al. 2008). Whether PICALM is implicated in LRP1-mediated and/or megalin-mediated transcytosis of Aβ across the BBB is presently not known.
Earlier studies have demonstrated that LRP1 and many of its ligands are deposited in senile plaques (Rebeck et al. 1995; Arelin et al. 2002). In addition to regulating Aβ clearance from brain (Shibata et al. 2000; Deane et al. 2004a; see below), it has been shown that the LRP1 cytoplasmic C-terminal domain interacts with APP's (Aβ-precursor protein) cytoplasmic domain via FE65, an LRP1 adaptor protein, which in turn influences APP processing and Aβ generation (Pietrzik et al. 2004; Waldron et al. 2008). It has also been demonstrated that LRP1 in neurons mediates Aβ cellular uptake and possibly retention in the brain via LRP1 ligands α2M and apoE (Narita et al. 1997; Qiu et al. 1999; DeMattos et al. 2004; Zerbinatti et al. 2004; Zerbinatti and Bu 2005; Deane et al. 2008). The exact implications of these findings for the development of Aβ pathology and cognitive decline remain, however, unclear.
Recent findings have revealed the roles of γ-secretase (the APP processing enzyme) and LRP1 in the inhibition of the inflammatory response suggesting that both proteins may serve as potential therapeutic targets for the modulation of inflammation (Zurhove et al. 2008). Given the importance of neuroinflammation in the pathogenesis of late-stage sporadic AD (McGeer and Rogers 1992; McGeer and McGeer 2004), it is tempting to speculate that the downregulation of LRP1 expression in the brain vascular cells observed in AD (Deane et al. 2004a; Bell et al. 2009) may also contribute to the development of neuroinflammation through a loss of LRP1-dependent inhibition of the interferon-γ promoter and lipopolysaccharide (LPS)-inducible inflammatory genes (Zurhove et al. 2008).
The amyloid hypothesis (Hardy and Allsop 1991; Selkoe 1991; Hardy and Higgins 1992; Hardy and Selkoe 2002) has been the basis for most work on the pathogenesis of AD over the past twenty years. More recently, however, both the direct Aβ neuronal toxicity and the clinical efficacy of the therapeutic approaches aimed at reducing Aβ levels in the brain of AD patients have been challenged by several investigators, as recently reviewed (for more details see, Hardy 2009). In this regard, it is of note that we proposed the two hit vascular hypothesis for AD a few years ago as an alternative mechanism for disease pathogenesis (Zlokovic 2005). According to the vascular hypothesis, an initial vascular damage to the brain mediated by hypoxia, perfusion stress and/or disruption of the BBB precedes Aβ accumulation (hit 1). Aβ then accumulates in the brain in response to this initial vascular damage in addition to re-entry of circulating Aβ into the brain and/or faulty Aβ clearance from the brain (hit 2). The two hit vascular hypothesis states that the role of Aβ in the disease process is to critically amplify the neurovascular damage and/or dysfunction which over time can lead to a chronic neurodegenerative process, cognitive decline and neuroinflammation. According to the vascular theory of AD, a primary damage to neurons by Aβ may contribute to but is not an absolute requirement for the development of a neurodegenerative process.
During the hit 1 disease stage, certain molecular mechanisms in the cerebrovascular system, such as the receptors for advanced glycation end products (RAGE) and LRP1, have been identified as important mediators of vascular damage. During normal brain aging or pathological brain aging accelerated by coexisting co-morbidities such as diabetes, hypertension, atherosclerosis, obesity, an acute ischemic insult, chronic hypoperfusion, brain trauma, etc., AGE proteins deposit in the basement membrane of the BBB and induce RAGE expression in the endothelium (Yan et al. 2010). RAGE-AGE interactions result in oxidant stress and expression of the cell adhesion proteins and proinflammatory cytokines (Yan et al. 2010). It is of note that Aβ also acts as a ligand for RAGE. It has been shown that RAGE mediates entry of circulating Aβ into the brain by a receptor-dependent transcytosis in those brain regions which express RAGE at the BBB during both normal and pathological aging (Mackic et al. 1998a; Deane et al. 2003). Alternatively, circulating Aβ can enter the brain across a disrupted BBB (Ujiie et al. 2003) which, again, is likely mediated by the proinflammatory cytokines in response to Aβ-RAGE interaction (Deane et al. 2003).
Pathological reductions in LRP1 expression at the BBB, on the other hand, may also initiate or contribute to the development of a proinflammatory brain endothelial cell phenotype associated with overexpression of interferon-γ and LPS-inducible inflammatory genes that are normally suppressed by the intracellular domain of LRP1 (LRP1-ICD; Fig 1a) that is translocated to the nucleus following γ-secretase-mediated cleavage at the plasma membrane (Zurhove et al. 2008). An increased expression of RAGE and downregulation of LRP1 at the BBB can suppress resting cerebral blood flow (CBF) and contribute to dysregulation of CBF responses to brain activation, respectively, as reported (Deane et al. 2003; Sagare et al. 2007a). RAGE expression has been found to be increased in brain endothelial cells and vascular smooth muscle cells (VSMC) in animal models of aging and AD as well as in human AD patients (Yan et al. 1996; Deane et al. 2003; Donahue et al. 2006; Miller et al. 2008), whereas LRP1 expression is decreased both at the BBB and in cerebral arterial VSMC (Shibata et al. 2000; Bading et al. 2002; Deane et al. 2004a; Donahue et al. 2006; Herring et al. 2008; Bell et al. 2009).
A moderate chronic hypoxia and/or chronic brain hypoperfusion can suppress the expression of the vascular-restricted mesenchyme homeobox gene 2 in brain endothelium in animal models and AD (Wu et al. 2005). Low expression of MEOX-2 mediates an aberrant brain angiogenesis characterized by premature capillary pruning and cell death ultimately leading to reductions in both microvascular length and resting CBF as well as downregulation of brain endothelial LRP1 (Wu et al. 2005). It has also been shown that an upregulation of two transcription factors that work in tandem, serum response factor and myocardin, in response to hypoxia and/or hypoperfusion leads to suppression of LRP1 in the VSMC in small cerebral arteries in animal models and in AD (Chow et al. 2007; Bell et al. 2009). Thus, hypoxia and perfusion stress can alter the phenotype of brain vascular cells amplifying the chronic neurovascular dysfunction that precedes neurodegenerative changes (Zlokovic 2005; Iadecola et al. 2009; de la Torre 2010). Brain ischemic events, ministrokes, brain hemorrhages, atherosclerosis, hypertension, diabetes, obesity, myocardial infarction, brain trauma and/or other vascular risk factors can set the stage for the development of chronic brain hypoxia, perfusion stress and/or BBB breakdown which may initiate neuronal degeneration independently of or synergistically with Aβ (for review see Zlokovic 2008).
To understand AD pathogenesis during the hit 2 phase, it is important to briefly review homeostasis of brain Aβ. Aβ concentration in the interstitial fluid in the brain is regulated by its rate of production from APP (Selkoe 2001a; Cirrito et al. 2003), influx of circulating Aβ into certain brain regions which depends on whether RAGE is expressed in the brain endothelium or not (Deane et al. 2003), rapid clearance across the BBB via LRP1 (Shibata et al. 2000; Deane et al. 2004a) which can be modulated by apoE isoforms (Zlokovic 1996; Martel et al. 1997; Tanzi et al. 2004; Moir and Tanzi 2005; Deane et al. 2008) and apoJ (Zlokovic et al. 1996; Calero et al. 2000; Bell et al. 2007), and the enzymatic degradation of Aβ (Selkoe 2001b). Although relatively little is known about the physiological functions of APP and Aβ, several studies have reported transport exchanges between peripheral and central Aβ pools from blood to brain (Zlokovic et al. 1993; Ghilardi et al. 1996; Martel et al. 1996; Poduslo et al. 1997; Mackic et al. 1998b, 2002; Banks et al. 2003; Deane et al. 2003; Ujiie et al. 2003) and from brain to blood (Shibata et al. 2000; Banks et al. 2003; Deane et al. 2004a, 2008; Ito et al. 2006, 2010; Bell et al. 2007).
In contrast to the fenestrated capillaries in peripheral organs which allow free exchange of many molecules between the blood and the ISF (Mann et al. 1985), the BBB is normally impermeable to small polar molecules, peptides and proteins (Zloković et al. 1985). Thus, transport of Aβ from blood to brain across the BBB requires the presence of a specialized transport system such as RAGE mediating a continuous re-entry of Aβ into the brain during the hit 2 stage that is associated with oxidant stress and pro-inflammatory response (Deane et al. 2003). It is noteworthy that RAGE-Aβ interactions at the BBB downregulates LRP1 (Deane et al. 2004b), thus making it unfavorable for Aβ clearance from the brain (see below). This in turn leads to a greater accumulation of different Aβ species in the brain (Kayed et al. 2003) including neurotoxic Aβ oligomers (Walsh et al. 2005; Lesné et al. 2006).
A continuous removal of Aβ from brain, blood and the entire organism is essential for preventing its accumulation in the brain (Zlokovic et al. 2000; Zlokovic 2008). As illustrated in Fig. 2, LRP1 plays a key role in the three-step serial clearance mechanism mediating Aβ elimination from the brain.
LRP1 is the main cell surface receptor mediating brain Aβ clearance at the BBB. It has been demonstrated that binding of Aβ to LRP1 at the abluminal side of the BBB in vivo initiates a rapid Aβ clearance across the BBB into the blood (Shibata et al. 2000; Deane et al. 2004a, 2008; Cirrito et al. 2005; Ito et al. 2006; Bell et al. 2007; Sagare et al. 2007a). Human Aβ injected into different brain regions in mice was found intact in murine plasma confirming its elimination from the brain (Shiiki et al. 2004; Bell et al. 2007). It has been shown that clearance of human 125I-labeled Aβ40 and Aβ42 injected into the caudate nucleus in mice is significantly inhibited (i.e., >70%) by RAP which blocks binding of ligands to both LRP1 and megalin, as well as by an LRP1 specific antibody, but not by antibodies against LRP2 (megalin), low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR) or apoE2R, thereby suggesting that LRP1 mediates clearance of Aβ (Shibata et al. 2000; Deane et al. 2004a). A significant reduction of human 125I-Aβ40 and 125I-Aβ42 clearance from the brain has been reported in transgenic RAP null mice exhibiting a greater than 70% decrease in the LRP1 levels in brain microvessels, but not in transgenic mice lacking LDLR or VLDLR, demonstrating again that cerebrovascular LRP1 mediates Aβ clearance across the BBB (Shibata et al. 2000; Deane et al. 2004a). It has been shown that LRP1 is involved in the vascular clearance of human 125I-Aβ40 from the rat secondary somatosensory cortex (S2 region) (Ito et al. 2006).
Using human specific ELISA to determine the levels of unlabeled human Aβ40 and Aβ42 in brain and plasma after their respective microinjections into the mouse caudate nucleus, it has been independently confirmed that both RAP and an anti-LRP1 antibody inhibit Aβ40 clearance from the brain and the appearance of intact Aβ in plasma, indicating LRP1 involvement (Bell et al. 2007). Furthermore, it has been shown that inhibition of LRP1 expression in brain microvessels of CD-1 mice by a cocktail of the LRP1 antisense RNAs results in impaired Aβ clearance from the brain associated with an increase in endogenous brain Aβ levels and impaired cognition (Jaeger et al. 2009). Studies in mouse models with genetically manipulated LRP1 expression at the BBB, such as RAP-null mice expressing substantially reduced LRP1 levels in brain microvessels and Tie-2-LRP1-cluster-IV transgenic mice expressing the LRP1 cluster IV minigene in cerebral microvasculature, have demonstrated increased and reduced mouse endogenous Aβ40 and Aβ42 brain levels, suggesting a major role of LRP1 in regulating brain clearance of Aβ under physiological conditions (Deane et al. 2004a; LaRue et al. 2007; Sagare et al. 2007b). Recently, it has been reported that the levels of LRP1 in brain microvessels can be increased by fluvastatin resulting in an enhanced Aβ clearance from the brain (Shinohara et al. 2010).
It is of note, in addition to LRP1-mediated clearance of Aβ from the brain, there is also clearance of different Aβ isoforms from the CSF to the blood (Ghersi-Egea et al. 1996; Monro et al. 2002; Silverberg et al. 2003). Although the preponderance of intraparenchymally-injected biologically active test-molecules in the rodent brain is likely reabsorbed across brain microvessels, the bulk flow clearance from brain interstitial fluid to CSF (Szentistvanyi et al. 1984) and along perivascular spaces (Weller et al. 2008) has been estimated to contribute up to 15-20%. In the case of Aβ, it has been determined that the CSF bulk flow in the normal mouse brain can mediate ~ 15% of total Aβ clearance (Shibata et al. 2000). It is conceivable that under pathological conditions associated with amyloid accumulation and diminished overall Aβ clearance from the CNS, the CSF bulk flow component can eventually become > 15%. However, this relative increase in the CSF clearance contribution would likely reflect a diminished LRP1-mediated Aβ clearance across the BBB, rather than an increase in the clearance capacity for Aβ through the choroid plexus and via the CSF pathway.
It is of note that LRP1 is also expressed in the choroid plexus epithelium of healthy young rats and its expression is sustained during aging (Johanson et al. 2006). Moreover, exposure to lead (Pb) has been shown to decrease expression of LRP1 in the choroid plexus epithelium that has been associated with Aβ accumulation in the choroid plexus (Behl et al. 2009, 2010). The exact role of LRP1 in the choroid plexus epithelium in mediating the CSF-to-blood Aβ clearance and for brain Aβ homeostasis during normal and pathological aging is an important topic deserving further research.
Studies using isolated murine cerebral microvessels have demonstrated LRP1-dependent clearance of Aβ40 and Aβ42 at the abluminal side of the BBB (Deane et al. 2004a). It has also been shown that RAP blocks an apoE-dependent uptake of Aβ peptides by astrocytes indicating that LRP1 and/or another member of the LDLR receptor family are likely involved in the astrocyte-mediated clearance of Aβ (Koistinaho et al. 2004). Studies using in vitro BBB models with a conditional immortalized cell line derived from brain capillary endothelial cells of transgenic rats expressing temperature-sensitive large T antigen (Yamada et al. 2008) and with the polarized Madin-Darby canine kidney cells expressing LRP1 mini-receptors (Nazer et al. 2008), have also importantly demonstrated the role of LRP1 in Aβ endothelial cellular uptake and endocytosis, respectively, resulting in Aβ clearance. Moreover, our preliminary observations using a human BBB in vitro model with primary brain endothelial cells and pericyte-conditioned media to direct LRP1 distribution mainly to the basolateral side of an endothelial monolayer have revealed LRP1-mediated transcytosis of Aβ40 and Aβ42 in the basolateral-to-apical direction corresponding to the abluminal and luminal sides of the BBB in vivo, respectively (E. A. Winkler, Y. Sallstrom, D. Zhu, R. Deane and B. V. Zlokovic, unpublished data).
LRP1 that is expressed at the abluminal side of the BBB was shown to mediate Aβ transport from brain to blood, but others have also reported that LRP1 can be utilized for delivery of therapeutics to the brain, as for example angiopeps (Demeule et al. 2008), implying that LRP1 might also be expressed at the luminal side of the BBB. The exact distribution of LRP1 between the luminal side of the BBB, the cytoplasmic endothelial pool and the abluminal side of the BBB is presently unknown. Our work in progress using high resolution confocal microscopy analysis indicates, however, that LRP1 is mainly confined to the abluminal side of the BBB, but a smaller portion of LRP1 is also expressed at the luminal side of the BBB (E. A. Winkler, Y. Sallstrom, D. Zhu, R. Deane and B. V. Zlokovic, unpublished data). It is possible that luminal LRP1 may participate in transport of angiopeps from blood-to-brain and that LRP1 in the cerebral vascular smooth muscle cells (Bell et al. 2009) can be utilized as well for delivery of therapeutics to the brain and cerebral arteries.
Reduced levels of LRP1 in brain microvessels correlating with endogenous Aβ deposition have been shown in a chronic hydrocephalus model in rats (Klinge et al. 2006). Moreover, reduced levels of LRP1 in brain microvessels associated with Aβ cerebrovascular and brain accumulation have been reported in AD patients (Shibata et al. 2000; Donahue et al. 2006). Several studies have indicated that LRP1 expression in the brain capillary endothelium is reduced during normal aging in rodents, non-human primates and humans, as well as in AD models and AD patients (Kang et al. 2000; Shibata et al. 2000; Bading et al. 2002; Deane et al. 2004a; Donahue et al. 2006; Bell and Zlokovic 2009). Similar reductions in LRP1 expression have been reported in cerebral vascular smooth muscle cells in small pial and intracerebral arteries regulating blood flow to the brain which was shown to be associated with Aβ accumulation within the wall of these brain arteries (Bell et al. 2009). Therefore, it is likely that LRP1 downregulation in the brain endothelium and vascular cells in patients with mild cognitive impairment during the hit 1 stage and in AD patients during the hit 2 stage would lead to faulty vascular Aβ clearance promoting cerebrovascular and focal parenchymal Aβ accumulations contributing to AD pathogenesis.
Reproducible and accurate measurements of Aβ clearance from the brain are challenging because of the hydrophobic nature of the full length peptide, possible conformational and structural changes of Aβ and heterogeneity of truncated Aβ fragments. Studies with 125I-labeled Aβ have generated critical data for the field. However, work with 125I-Aβ preparations also requires special precautions due to rapid radiolysis of the labeled peptide. We have recommended that the radiolabeled Aβ should be used either immediately after labeling within 24 h or alternatively can be stored in ethanol over a short period of time (i.e., 3-4 days), and re-purified before use on the day of the experiment by HPLC to eliminate free iodine and possible Aβ degradation products, and separate mono-iodinated from di-iodinated Aβ species and oxidized from reduced Aβ (LaRue et al. 2004). It is of note, Aβ radioiodination by a mild lactoperoxidase method typically provides less damage to the peptide than a more robust chloramine-T method (LaRue et al. 2004). In brain clearance studies, the integrity of 125I-Aβ in the brain should be additionally confirmed by different analytical methods such as sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and HPLC (Deane et al. 2004a, 2008).
It has also been raised that iodination can potentially introduce a conformational change in the peptide. Therefore, more recently some important control measurements have been performed by different groups (as discussed above) to complement the radiotracer studies. This includes, but is not limited to the use of unlabeled Aβ and measurements of its concentrations in brain and blood by ELISA, as well as measurements of endogenous Aβ levels in transgenic models with manipulated LRP1 expression, or LRP1 silencing and/or by pharmacologically manipulating LRP1 expression in brain microvessels.
In a recent paper, Ito et al. (2010) have confirmed 125I-Aβ40 clearance from the mouse S2 region using an established brain clearance technique (Kakee et al. 1996), but failed to demonstrate inhibition of Aβ clearance by RAP. Based on this single negative result with RAP, Ito et al. have suggested that the members of the LDLR receptor family including LRP1 do not participate in Aβ40 clearance, challenging findings from several different groups that have demonstrated a major role of LRP1 in Aβ clearance, as discussed above. However, Ito et al. have not performed any control experiments to determine 125I-Aβ integrity immediately prior to its use on the day of the experiment and/or at the end of the experiment in brain extracts. They also did not use unlabeled Aβ as a control for radiolabeled Aβ. Moreover, they have not employed any complementary approach to determine the role of LRP1 in Aβ clearance, such as blockade of LRP1 by an LRP1-specific antibody, inhibition of LRP1 expression by LRP1 silencing by siRNA and/or antisense RNAs strategies, or use of transgenic models with genetically manipulated LRP1 expression.
By analyzing the experimental design in Ito et al.'s (2010) study, one can find out that Aβ40 was radiolabeled with chloramine-T and after labeling it was lyophilized and mixed with different excipients including aprotinin, as per the PerkinElmer Technical Data Certificate of Analysis, NEX361 sheet and Dr. Terasaki's (senior author in Ito et al. 2010) personal communication to us. Aprotinin is a protease inhibitor, but it unfortunately also binds to LRP1 and prevents an LRP1-dependent uptake of RAP (Demeule et al. 2008), which therefore could potentially interfere with Aβ clearance measurements in vivo as performed by Ito et al. (2010). According to table 1 [from Ito et al. 2010], one can calculate the final concentration of aprotinin in the injectate in their experiments which was about 400 KIU (Kallikrein Inhibitor Unit)/mL of aprotinin or about 8.6 μM.
To test whether co-administered aprotinin interferes with the RAP-mediated blockade of Aβ clearance, we have determined clearance of unlabeled Aβ40 from the mouse caudate nucleus in the presence or absence of RAP and with or without aprotinin by using human specific Aβ40 ELISA over a 30 min period of time. In all experiments, 14C-inulin (an inert polar molecule) was administered into the brain simultaneously with Aβ as a reference standard (Shibata et al. 2000). As we have reported previously by using unlabeled Aβ (Bell et al. 2007), RAP (5 μM) decreased human Aβ40 clearance from the brain by ~50% (Fig. 3a; for details of calculations please see Bell et al. 2007). However, in the presence of aprotinin (8.6 μM), RAP did not have any significant effect on Aβ40 clearance (Fig. 3a) corroborating data by Ito et al. (2010). The appearance of an intact human Aβ40 in plasma was abolished by RAP in the absence of aprotinin (Fig. 3b). However, the presence of aprotinin completely inhibited RAP-mediated blockade of Aβ brain-to-blood transfer (Fig. 3b).
Consistent with a previous report (Ito et al. 2010), Aβ recovery in brain and its appearance in plasma after intracerebral administration were not affected by aprotinin alone (Fig. 3a and b), suggesting that aportinin alone does not influence LRP1-mediated Aβ clearance from brain and that at least in vivo Aβ and aprotinin likely bind to different exosites on LRP1. Overall, this data shows that only in the presence of RAP aprotinin substantially affects the measurement of Aβ clearance from the mouse brain.
As aprotinin prevented RAP-mediated inhibition of Aβ40 clearance from the brain, we next explored whether aprotinin interacts directly with RAP. Here, we have demonstrated by ELISA that aprotinin binds to immobilized RAP (Fig. 3c). By incubating aprotinin and RAP for 1 h at 37°C we have additionally confirmed by immunoblotting analysis after cross-linking with bis[sulfosuccinimidyl]suberate (BS3) that aprotinin interacts directly with RAP (Fig. 3d). Thus, binding of RAP to aprotinin would prevent RAP from blocking 125I-Aβ40 binding to LRP1 at the abluminal side of the BBB in vivo which in turn may confound measurements of Aβ clearance and data interpretation.
We have demonstrated that circulating plasma sLRP1 provides a key endogenous peripheral ‘sink’ activity for Aβ by promoting a continuous removal of Aβ from brain (Sagare et al. 2007a). In neurologically healthy humans and mice, sLRP1 normally binds > 70% of circulating Aβ preventing free Aβ access to the brain (Sagare et al. 2007a) (Fig. 1a). In AD patients and AD transgenic mice, however, Aβ binding to sLRP1 is compromised because of increased levels of oxidized sLRP1 which does not bind Aβ (Sagare et al. 2007a) resulting in elevated levels of free Aβ40 and Aβ42 that can re-enter the brain via RAGE-mediated transport (Deane et al. 2003; Ujiie et al. 2003; Donahue et al. 2006; Sagare et al. 2007a).
In the human hippocampus, it was shown that RAGE expression in brain endothelium is increased with advanced AD compared to early stage AD and/or individuals with mild cognitive impairment (MCI) (Miller et al. 2008) which may further contribute to Aβ accumulation into the brain via enhanced Aβ influx from blood to brain. Moreover it has been recently shown that a diminished sLRP1-Aβ ‘sink’ activity precedes an increase in the tau/Aβ42 CSF ratio and a drop in global cognitive decline in individuals with MCI converting into AD, and is therefore a useful early biomarker for AD-type dementia (Sagare et al. 2009). It has also been shown that recombinant LRP1 fragments can effectively replace oxidized sLRP1 and sequester free Aβ in plasma in AD patients and AD transgenic mice ultimately reducing Aβ-related pathology in the brain (Sagare et al. 2007a). It is of note, a recent Phase II clinical trial in patients with mild AD with Baxter's intravenous immunoglobulin preparation Gammagard Liquid containing both sLRP1 and anti-RAGE immunoglobulins (Weber et al. 2009) has shown encouraging results (Relkin et al. 2009). It has been suggested that both sLRP1 and anti-RAGE may contribute to the observed beneficial effects of GGL by improving peripheral sink for Aβ and preventing Aβ influx into the brain, respectively (Dodel et al. 2010).
In aged Squirrel monkeys, Aβ systemic clearance is reduced and is associated with increased Aβ levels in the brain (Mackic et al. 1998b, 2002). Also, an increased entry of circulating Aβ42 into the brain and its deposition onto senile plaques in aged Rhesus monkeys (Mackic et al. 2002) or accumulation of circulating Aβ40 in the cerebral vessels in aged Squirrel monkeys with CAA (Ghilardi et al. 1996), have been demonstrated. An age-dependent reduction in the systemic Aβ clearance may diminish the ‘sink action’ for Aβ clearance from the brain which in turn could increase the RAGE-dependent free Aβ transport across the BBB into brain regions expressing RAGE.
It has also been reported that a rapid peripheral clearance of Aβ is mediated mainly by LRP1 in the liver (Tamaki et al. 2006). Using the perfused rat liver preparation, Tamaki et al. (2007) were able to convincingly show that RAP blocks 125I-Aβ uptake by the liver likely because in these experiments RAP was pre-infused into the liver before administration of 125I-labeled Aβ and aprotinin, and was not mixed with Aβ/aprotinin. In addition, the dilution of aprotinin in the liver uptake measurements (Tamaki et al. 2007) was at least by ~ 40-fold greater than in the brain clearance measurements (Ito et al. 2010). These differences in the experimental design were likely to minimize the interaction between RAP and aprotinin in the Aβ liver uptake study.
It is of note that reduced hepatic LRP1 levels have been shown to be associated with decreased peripheral Aβ clearance in the aged rats (Tamaki et al. 2006, 2007). In addition, both sLRP1-Aβ complexes and free Aβ are eliminated via the kidneys (Sagare et al. 2007a), but whether LRP1 is involved in Aβ clearance by the kidneys as in the liver is presently unknown.
In conclusion, we have reviewed recent evidence suggesting that LRP1 has a major role in regulating brain and systemic clearance of Alzheimer's Aβ. Specifically, we have discussed the role of LRP1 during hit 1 (i.e., before Aβ accumulation) and hit 2 (i.e., the Aβ accumulation stage) phases of AD pathogenesis. According to our vascular two hit hypothesis for AD an initial vascular damage such as hypoxia, perfusion stress and/or disruption of the BBB functional integrity drive the disease process and Aβ accumulation in the brain. The multiple regulatory roles of cell surface LRP1 at the BBB, the circulating soluble LRP1 and LRP1 in the peripheral organs such as liver suggest a three-level serial LRP1 homeostatic mechanism for Aβ clearance from the brain that could be a major, but still underexplored therapeutic target in AD.
It has been shown that pharmacological and/or gene therapy strategies to increase the levels of LRP1 in the cerebrovascular system and at the BBB may hold potential to alleviate initial vascular damage by suppressing brain endothelial cell activation during the hit 1 stage, and prevent and/or reduce Aβ accumulation during both the hit 1 and hit 2 stages of AD pathogenesis. The oxidized sLRP1 in plasma, which does not bind peripheral Aβ and therefore does not have an Aβ ‘sink’ activity, is also an important early biomarker in MCI individuals converting into AD as well as in AD patients. Thus, replacement therapy for the native oxidized circulating sLRP1 with recombinant LRP1 clusters may help maintain the peripheral Aβ ‘sink’ activity at an early stage of the disease in patients with MCI by reducing the influx of circulating Aβ into the brain which may slow down disease progression. Finally, approaches to increase LRP1 expression in peripheral organs, such as liver, through pharmacologic agents and/or gene therapy might help promote systemic Aβ elimination, which has been shown to improve peripheral Aβ-‘sink’ activity by reducing sLRP1-Aβ and free Aβ levels in plasma and promoting Aβ clearance from the brain.
As a note of caution, we would like to stress that the development of LRP1-based therapies for AD requires careful toxicity and safety monitoring of unwanted potential side effects given that LRP1 participates in multiple control systems in the body, ranging from the cellular transport and metabolism of cholesterol to anticoagulation and inflammation. However, our preliminary findings suggest that LRP1-based therapeutics such as the recombinant LRP1 clusters (Zlokovic et al. 2009) can be tailored by genetic engineering to be more specifically directed at Aβ with minimal effects on other systems in the body. These new LRP1 variants produced by site-directed LRP1 mutagenesis may have potential either as recombinant proteins adapted for systemic administration and/or as Aβ-selective LRP1 gene constructs adapted for tissue-specific expression in the brain, liver and/or other peripheral organs.
This study was supported by US National Institutes of Health (NIH) grants R37AG023084 and R37NS34467 to BVZ.